82
Views
0
CrossRef citations to date
0
Altmetric
Research Article

Association between plasminogen activator inhibitor-1 4G/5G gene polymorphism and immunoglobulin A nephropathy susceptibility

&
Pages 63-66 | Received 08 May 2014, Accepted 19 May 2014, Published online: 11 Jun 2014
 

Abstract

The association between plasminogen activator inhibitor-1 (PAI-1) 4G/5G gene polymorphism and immunoglobulin A nephropathy (IgAN) risk is still controversial. A meta-analysis was performed to evaluate the association between PAI-1 4G/5G gene polymorphism and IgAN susceptibility. A predefined literature search and selection of eligible relevant studies were performed to collect data from electronic database. Four articles were identified for the analysis of association between PAI-1 4G/5G gene polymorphism and IgAN risk. 4G allele was not associated with IgAN susceptibility in overall populations and in Asians. Furthermore, 4G/4G and 5G/5G genotype were not associated with IgAN for overall populations, Asians. In conclusion, PAI-1 4G/5G gene polymorphism was not associated with IgAN risk in overall populations and in Asians. However, more studies should be performed in the future.

Declaration of interest

The authors report no conflicts of interest. The authors alone are responsible for the content and writing of this article. This study was supported by the sub-item of 985 Project Foundation of Sun Yat-Sen (The Hundred Talents Program Foundation; No. 88000-3311300).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.